Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesCirculating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)
European Journal of Cancer, 10/02/09
Fusi A et al. – Detection of circulating tumour cells by RT-PCR for tyrosinase and Mart-1/Melan-A was a time-dependent moderate prognostic factor for subsequent development of distant metastasis in stage III melanoma patients.
Methods- Serial testing for tyrosinase and Mart-1/Melan-A transcripts in peripheral blood
- Performed every 6 months over maximum period of 60 months in subset of patients enrolled in EORTC 18991 phase 3 trial
- Univariate and multivariate analyses performed to estimate role of RT-PCR as prognostic and predictive factor for distant metastasis-free survival
- Among 299 patients who underwent RT-PCR analyses, 109 (36.5%) had at least 1 positive sample
- Cumulative rate of positive results similar in two treatment groups, as DMFS from first RT-PCR positivity
- Cox time-dependent analysis indicated significantly higher risk of developing distant metastasis in patients with positive sample as compared to those with a negative one
- Results were comparable in the 2 treatment groups, indicating that RT-PCR assessment was not predictive for treatment outcome
Today in Dermatologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A Multimarker Prognostic Assay for Primary Cutaneous Melanoma
Clinical Cancer Research, 11/06/09
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
British Journal of Cancer, 11/03/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Annals of Oncology, 11/06/09
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia
Journal of Clinical Oncology, 11/09/09
Sponsor
Article Search
Sponsor
Sponsor